Macrogenics (MGNX) EBITDA (2012 - 2026)

Macrogenics (MGNX) has 15 years of EBITDA data on file, last reported at -$36.8 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$36.8 million, up 10.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$70.4 million (down 26.19% YoY), and the FY2025 annual result was -$74.6 million, down 11.4% from the prior year.
• EBITDA eased to -$36.8 million in Q1 2026 per MGNX's latest filing, from -$14.1 million in the prior quarter.
• Over five years, EBITDA peaked at $57.4 million in Q2 2023 and troughed at -$66.7 million in Q1 2022.
• A 5-year average of -$18.1 million and a median of -$36.3 million in 2025 frame the typical range for EBITDA.
• On a YoY basis, EBITDA climbed as much as 238.8% in 2023 and fell as far as 456.65% in 2023.
• A 5-year view of EBITDA shows it stood at $12.9 million in 2022, then slumped by 456.65% to -$46.0 million in 2023, then jumped by 66.49% to -$15.4 million in 2024, then advanced by 8.44% to -$14.1 million in 2025, then sank by 160.71% to -$36.8 million in 2026.
• Business Quant data shows MGNX's EBITDA at -$36.8 million in Q1 2026, -$14.1 million in Q4 2025, and $16.8 million in Q3 2025.